ATE171072T1 - Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen - Google Patents

Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen

Info

Publication number
ATE171072T1
ATE171072T1 AT91915386T AT91915386T ATE171072T1 AT E171072 T1 ATE171072 T1 AT E171072T1 AT 91915386 T AT91915386 T AT 91915386T AT 91915386 T AT91915386 T AT 91915386T AT E171072 T1 ATE171072 T1 AT E171072T1
Authority
AT
Austria
Prior art keywords
active substances
targeting drugs
conjugates
receptor conjugates
receptor
Prior art date
Application number
AT91915386T
Other languages
English (en)
Inventor
Howard C Krivan
Arne Lennart Ingemar Blomberg
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Application granted granted Critical
Publication of ATE171072T1 publication Critical patent/ATE171072T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91915386T 1991-07-31 1991-07-31 Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen ATE171072T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002114629A CA2114629C (en) 1991-07-31 1991-07-31 Receptor conjugates for targeting antibiotics to bacteria
PCT/US1991/005422 WO1993002709A1 (en) 1991-07-31 1991-07-31 Receptor conjugates for targeting drugs and other agents

Publications (1)

Publication Number Publication Date
ATE171072T1 true ATE171072T1 (de) 1998-10-15

Family

ID=25676975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915386T ATE171072T1 (de) 1991-07-31 1991-07-31 Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen

Country Status (8)

Country Link
EP (1) EP0598719B1 (de)
JP (1) JP3369555B2 (de)
AT (1) ATE171072T1 (de)
CA (1) CA2114629C (de)
DE (1) DE69130235T2 (de)
DK (1) DK0598719T3 (de)
ES (1) ES2123514T3 (de)
WO (1) WO1993002709A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
JPH08133971A (ja) * 1994-09-16 1996-05-28 Toyama Chem Co Ltd 抗ヘリコバクター剤
CA2253204A1 (en) * 1996-05-03 1997-11-13 Roger S. Cubicciotti Prodrug compositions and drug delivery methods using synthetic receptors
JP7534796B2 (ja) * 2019-01-08 2024-08-15 ユニバーシティー オブ ジョージア リサーチ ファウンデーション， インコーポレイテッド 標的化ナノ粒子、及び真菌感染に関連するそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1165238A (en) * 1980-03-12 1984-04-10 Demetrios P. Papahadjopoulos Activated liposomes and method
SE8501613D0 (sv) * 1985-04-01 1985-04-01 Bio Carb Ab Foreningar for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
GB8628398D0 (en) * 1986-11-27 1986-12-31 Central Blood Lab Authority Pharmaceutically-active conjugates
DE3711724A1 (de) * 1987-04-07 1988-10-20 Harro Boerner Medizinische Kom System zum einwirken auf, insbesondere zerstoeren von viren
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
CA2017739A1 (en) * 1989-07-18 1991-01-18 Leslie S. Hollis Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents
AU6521790A (en) * 1989-10-13 1991-05-16 Hans Schreier Lipophilic acylpyrazinamide prodrugs

Also Published As

Publication number Publication date
DK0598719T3 (da) 1999-06-14
JPH06511466A (ja) 1994-12-22
WO1993002709A1 (en) 1993-02-18
DE69130235D1 (de) 1998-10-22
CA2114629C (en) 2003-01-14
EP0598719B1 (de) 1998-09-16
EP0598719A1 (de) 1994-06-01
ES2123514T3 (es) 1999-01-16
DE69130235T2 (de) 1999-02-11
JP3369555B2 (ja) 2003-01-20
CA2114629A1 (en) 1993-02-18

Similar Documents

Publication Publication Date Title
NO995349D0 (no) Multivalent vaksinasjonssammensetning med blandet baerer
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
BG101118A (en) Therapeutical compounds
PT688789E (pt) Processo de lipopeptideos processo para a sua preparacao e sua utilizacao
IL119207A0 (en) Treatment of tinnitus using neuroprotective agents
EP0869801A4 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE171072T1 (de) Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2174272T3 (es) Utilizacion del (r)-verapamilo como medicamento para el tratamiento de la angina.
PT89582A (pt) Processo para a preparacao de antibioticos beta-lactamicos uteis como medicamentos
ES2076107B1 (es) Derivados de antibioticos macrolidos de anillos de 16 miembros.
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee